Drug intelligence / Profile preview

amphotericin b

Development stage
Approved
Lead developer
Bristol Myers Squibb
Modality
Small Molecules
Administration
Intravenous, Intrathecal, Topical, Oral, Inhalation, Ophthalmic, Intravesical
01

Overview

Amphotericin B is a polyene antifungal medication used primarily to treat serious and potentially life-threatening systemic fungal infections and leishmaniasis. It is not indicated for minor fungal infections. The drug acts by binding to ergosterol, a key component of fungal cell membranes, forming pores that disrupt membrane integrity and cause leakage of monovalent ions (Na+, K+, H+, Cl-), leading to cell death. Amphotericin B has a higher affinity for ergosterol than cholesterol but can also bind mammalian cell membranes, contributing to its toxicity profile. It is available in several formulations including conventional (deoxycholate) and lipid-based forms such as liposomal amphotericin B (AmBisome). The drug was originally developed in the 1950s.

Brand names
FungizoneAmphocinFungizone For Tissue CultureAmBisome
Other names
amphotericin-bamphotericin B deoxycholate
02

Targets

Ergosterol

Beyond the preview

Go deeper on amphotericin b.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on amphotericin b.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call